Efficacy of the Dual PI3K and mTOR Inhibitor NVP-BEZ235 in Combination With Imatinib Mesylate Against Chronic Myelogenous Leukemia Cell Lines
Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s132092
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2017
Authors
Publisher
Informa UK Limited